Literature DB >> 23617437

Counting fetal alcohol spectrum disorder in Australia: the evidence and the challenges.

Lucy Burns1, Courtney Breen, Carol Bower, Colleen O' Leary, Elizabeth Jane Elliott.   

Abstract

ISSUES: Alcohol exposure in utero is associated with a range of adverse outcomes in pregnancy and can cause long-term disability. Fetal alcohol spectrum disorder (FASD) is an umbrella term to describe a range of effects from prenatal alcohol exposure including fetal alcohol syndrome (FAS). Determining the prevalence of FASD is challenging. APPROACH: This narrative review collates information on the prevalence of FASD in Australia and documents the various methods used for attaining estimates and the limitations of the available data. KEY
FINDINGS: Birth prevalence of FASD is most commonly measured through clinic-based studies, passive surveillance systems and active case ascertainment. Alcohol use in pregnancy and FAS in Australia is predominantly monitored through passive surveillance systems and under-ascertainment of cases is likely. State- and territory-based studies have reported birth prevalence rates of FAS of between 0.01 and 0.68 per 1000 live births. Prevalence rates of FASD have not been estimated in Australia. As reflected in the international data, Australian studies have found higher rates of FAS among some Indigenous communities. This likely reflects patterns of alcohol use and other socioeconomic risk factors. IMPLICATIONS: Under-recognition of FASD reflects incomplete and inconsistent data collections recording alcohol use in pregnancy, lack of awareness among health professionals and a lack of diagnostic and support services.
CONCLUSION: Accurate measurement of FASD prevalence is crucial to inform policy, resource and service development in the areas of health, education, justice and community. There is a need for consensus on the collection and best use of data. [Burns L, Breen C, Bower C, O' Leary C, Elliott EJ. Counting fetal alcohol spectrum disorders in Australia: the evidence and the challenges. Drug Alcohol Rev 2013;32:461-467].
© 2013 Australasian Professional Society on Alcohol and other Drugs.

Entities:  

Keywords:  FASD; alcohol; pregnancy

Mesh:

Year:  2013        PMID: 23617437     DOI: 10.1111/dar.12047

Source DB:  PubMed          Journal:  Drug Alcohol Rev        ISSN: 0959-5236


  6 in total

1.  Invited commentary on Australian fetal alcohol spectrum disorder diagnostic guidelines.

Authors:  Susan J Astley
Journal:  BMC Pediatr       Date:  2014-04-01       Impact factor: 2.125

2.  Exploring service providers' perspectives on the prevention and management of fetal alcohol spectrum disorders in South Africa: a qualitative study.

Authors:  Babatope O Adebiyi; Ferdinand C Mukumbang; Lizahn G Cloete; Anna-Marie Beytell
Journal:  BMC Public Health       Date:  2018-11-06       Impact factor: 3.295

Review 3.  A systematic review of prevention interventions to reduce prenatal alcohol exposure and fetal alcohol spectrum disorder in indigenous communities.

Authors:  Martyn Symons; Rebecca Anne Pedruzzi; Kaashifah Bruce; Elizabeth Milne
Journal:  BMC Public Health       Date:  2018-11-03       Impact factor: 3.295

4.  Navigating complexity to support justice-involved youth with FASD and other neurodevelopmental disabilities: needs and challenges of a regional workforce.

Authors:  Rebecca Anne Pedruzzi; Olivia Hamilton; Helena H A Hodgson; Elizabeth Connor; Elvira Johnson; James Fitzpatrick
Journal:  Health Justice       Date:  2021-02-27

5.  The Alcohol Industry and Social Responsibility: Links to FASD.

Authors:  Peter Choate; Dorothy Badry; Kerryn Bagley
Journal:  Int J Environ Res Public Health       Date:  2022-06-24       Impact factor: 4.614

6.  Adverse childhood experiences, associated stressors and comorbidities in children and youth with fetal alcohol spectrum disorder across the justice and child protection settings in Western Australia.

Authors:  Grace Kuen Yee Tan; Martyn Symons; James Fitzpatrick; Sophia G Connor; Donna Cross; Carmela F Pestell
Journal:  BMC Pediatr       Date:  2022-10-10       Impact factor: 2.567

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.